Zolpeduar

Quick links to important sections

Zolpeduar

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zolpeduar

Quick Facts

Property Description
Active ingredient Zolpidem tartrate
Form Sublingual tablet, oral tablet
Pharmacological class Sedative-hypnotic drug (Nonbenzodiazepine hypnotic / Z-drug)
Origin Synthetic chemical compound
Prescription Status Prescription-only medicine (Rx)

What Type of Medicine is Zolpeduar and Its Active Ingredient?

Zolpeduar is a synthetic pharmaceutical preparation classified as a sedative-hypnotic drug used to facilitate the onset and maintenance of sleep in adults. The medication is a single-active ingredient product where the primary compound is Zolpidem tartrate. This substance is specifically recognized as a nonbenzodiazepine hypnotic, colloquially known as a Z-drug, due to its unique chemical structure as an Imidazopyridine derivative. This classification is clinically recognized for differentiating its mechanism from older sedative agents, supporting its use in addressing adult sleep difficulties.

Zolpeduar's General Purpose and Dosage Forms

The general therapeutic purpose of Zolpeduar is to facilitate sleep by enhancing the brain's natural inhibitory pathways, leading to sedation and hypnosis. Its action as a GABA-A receptor agonist promotes sleep initiation and maintenance, classifying it as a rapid-onset sleep aid. Therefore, the medication's overall purpose is to provide short-term pharmacological support for adults struggling to achieve a restful state. A key distinguishing factor for this preparation is its primary presentation as a sublingual tablet (sub-lingual route of administration), allowing for dissolution under the tongue. The availability of this distinct form, alongside potential standard oral tablet variants, ensures that the medication is structured to address both the difficulty in falling asleep and the struggle to stay asleep.

Regulatory References

  1. FDA Drug Label (Zolpidem)

What side effects are possible with Zolpeduar?

Zolpeduar: Possible Side Effects and Safety Information

Critical Safety Warnings

Government regulatory authorities require a Boxed Warning regarding the risk of serious injuries and death from Complex Sleep Behaviors (CSBs), which include activities such as sleep-driving, sleepwalking, making phone calls, or preparing and eating food while not fully awake, with no memory of the event afterward. These behaviors can occur after the first dose, even at recommended dosages. Zolpeduar is formally contraindicated (must not be used) in patients who have experienced a CSB after taking the drug.

Other Serious Adverse Reactions

Potentially life-threatening severe anaphylactic and anaphylactoid reactions have been reported, including angioedema (swelling of the tongue, glottis, or larynx) that can lead to fatal airway obstruction. The medication is also contraindicated in patients with a known hypersensitivity to the drug. Additionally, abnormal thinking and behavioral changes—such as agitation, hallucinations, and bizarre behavior—have occurred, as well as the worsening of depression and the emergence of suicidal ideation.

Common Adverse Reactions

The most commonly reported side effects in clinical trials include drowsiness (daytime sleepiness), dizziness, headache, and diarrhea. The risk of next-day impairment, including impaired driving and coordination, is dose-dependent and increases significantly if less than a full night's sleep (7 to 8 hours) is obtained.

Population-Specific Safety Considerations

  • Females are advised to use a lower starting dose due to slower drug elimination, which increases the risk of next-morning impairment.
  • Elderly and Debilitated Patients are recommended to use a lower dose due to heightened sensitivity to the CNS-depressant effects and an increased risk of falls.
  • Hepatic Impairment: A lower dose is advised for mild to moderate hepatic impairment, and the drug is contraindicated in severe hepatic impairment due to the risk of hepatic encephalopathy.

Risk of Dependence and Withdrawal

Zolpeduar is classified as a Schedule IV controlled substance due to the potential for abuse, misuse, tolerance, and physical dependence. Abrupt discontinuation, particularly after prolonged use, may lead to withdrawal symptoms.

Overdose and Emergency Response

Zolpidem tartrate overdose primarily causes Central Nervous System (CNS) depression. Documented manifestations start with severe drowsiness and extreme lethargy, potentially leading to impaired motor control, such as staggering or clumsiness. The severity can progress rapidly, resulting in a loss of consciousness and advancing to a deep coma. Paradoxical reactions, including agitation or hallucinations, have also been documented in severe cases.

When to Seek Urgent Help

Regulators mandate that immediate medical attention or emergency treatment must be sought if an overdose is suspected. Urgent medical help is specifically required if the patient exhibits trouble breathing (a sign of respiratory depression) or a loss of consciousness. The most significant life-threatening outcomes documented in regulatory sources are respiratory depression and cardiovascular compromise. The risk of severe, sometimes fatal, outcomes is significantly increased when Zolpeduar is taken alongside alcohol or other CNS depressants.

Management and Considerations

Official management is based on general symptomatic and supportive measures. While the reversal agent Flumazenil is cited in management protocols, its use is noted to be medically judicious due to the potential risk of inducing seizures. A key procedural constraint is that the drug is not dialyzable. Elderly patients and individuals with hepatic impairment are noted to have increased sensitivity, potentially leading to greater toxicity.

Therapeutic Uses of Zolpeduar

What Zolpeduar Treats: Main Uses and Benefits

Zolpeduar is generally used for the short-term treatment of insomnia in adults, a therapeutic domain where symptoms related to heightened physiological activity interfere with functional stability. The medication is applied across conditions presenting with acute or disruptive episodes of sleeplessness.

It is considered relevant for easing difficulty with sleep initiation and supporting sleep maintenance, which are key symptom domains addressed. The drug is commonly used to help manage both delayed sleep onset and frequent night-time awakenings in clinical settings that involve acute or unstable symptom patterns. This supportive approach helps patients cope more steadily with difficult episodes and contributes to easing the overall symptom load.

The short-term use context is important: “It is applied during phases when symptoms become more noticeable, offers symptomatic relief that helps patients cope more steadily and ease the overall symptom burden.”


Quick Fact: Therapeutic Focus

Focus Symptom Axis Benefit Provided
Primary Indication Delayed sleep onset Easing difficulty with sleep induction
Context Transient/Acute episodes Supports patients during difficult episodes

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Zolpeduar

Official regulatory documents define the population eligible to use Zolpeduar (Zolpidem tartrate) as adults (18 years and older) who do not have specific contraindications. Use is contraindicated in several groups due to severe risks.

Classification Population or Condition
Contraindicated Known hypersensitivity to zolpidem; patients with a history of complex sleep behaviors (e.g., sleep-driving) after taking zolpidem [Source 1.2, 1.4].
Contraindicated Patients with severe hepatic (liver) impairment, sleep apnoea syndrome, or severe respiratory insufficiency [Source 1.4, 2.4].
Not Recommended Children and adolescents (under 18 years); pregnant or breastfeeding individuals, due to potential risk to the fetus or infant and unestablished safety/effectiveness [Source 1.7, 3.3].
Restricted Use Older adults (geriatric patients); patients with mild to moderate hepatic impairment [Source 2.1, 2.3].

Eligibility-related restrictions also apply to patients with a history of substance/alcohol abuse, who require caution and supervision. While renal impairment does not generally require dosage adjustment, close monitoring is advised. These categories define strict, label-based exclusion or caution.

What should I know about interactions with other medicines?

Zolpeduar (zolpidem) interacts with other substances primarily through its central nervous system (CNS) depressant activity and its metabolism via the CYP3A4 enzyme in the liver.

Major Interaction Categories

  • CNS Depressants and Alcohol: The co-administration of Zolpeduar with alcohol or other CNS depressants (e.g., opioids, benzodiazepines, tricyclic antidepressants) significantly increases the risk of additive CNS depression. This can lead to increased drowsiness, psychomotor impairment, and the potential for respiratory depression. Dosage adjustments for Zolpeduar and any concomitant CNS depressants may be required.
  • Complex Sleep Behaviors: The risk of serious complex sleep behaviors (such as sleep-driving or walking while not fully awake) is increased when Zolpeduar is combined with alcohol or other CNS depressants. If a patient experiences a complex sleep behavior, Zolpeduar must be discontinued immediately.

Pharmacokinetic Interactions

  • CYP3A4 Inhibitors: Medicines that inhibit the CYP3A4 enzyme, such as ketoconazole, can increase the blood levels of zolpidem, potentially magnifying its effects. A lower dose of Zolpeduar may be considered with potent inhibitors.
  • CYP3A4 Inducers: Conversely, enzyme inducers like rifampin or the herbal product St. John's wort can decrease zolpidem blood levels, which may reduce the medicine's effectiveness.

Mechanism of Action

Zolpeduar is a non-benzodiazepine agent that acts within the central nervous system (CNS) as a positive allosteric modulator of the GABAA receptor complex. This interaction increases the functional activity of the major inhibitory neurotransmitter, GABA (gamma-aminobutyric acid).


GABA-A Receptor Engagement

Zolpeduar binds specifically to the benzodiazepine site on the GABAA receptor, enhancing the inhibitory signaling cascade. The agent exhibits a high degree of binding selectivity for receptors containing the alpha1 subunit, which are functionally relevant to central inhibitory signaling.


Modulation of Neuronal Excitability

By boosting the inhibitory potential of GABA, Zolpeduar increases the frequency of chloride channel opening, causing hyperpolarization of the neuronal membrane. This physiological effect modulates the firing rate of alpha1-expressing neurons, resulting in a net reduction in systemic neuronal firing rates and modifying the output of overly active neuronal processes within targeted circuits.

Dosage and Administration Information

How to Use Zolpeduar: Official Administration Guidelines

Zolpeduar (Zolpidem tartrate) is administered according to established guidelines, defining the authorized dosage forms, routes, and timing. The medication is intended solely for short-term use, typically ranging from a few days up to four weeks. If difficulty sleeping persists beyond 7 to 10 days of treatment, a medical re-evaluation is required.

Administration Routes and Scheduling

The approved routes are Oral (for immediate-release and extended-release tablets) and Sublingual (for tablets dissolved under the tongue). All formulations are limited to a single dose per night and must be taken only when the user has the opportunity for a full night's sleep (at least 7 to 8 hours) remaining. The dose must not be readministered during the same night.

  • Oral (Immediate-Release/CR): Must be swallowed whole. Extended-release tablets (CR) must not be crushed, divided, or chewed. Taking the dose with or immediately after a meal may slow the onset of action.
  • Sublingual: These tablets must be placed under the tongue and allowed to disintegrate completely.

Official Dosing and Population Adjustments

Dosage is determined by formulation and patient population:

Population / Form Initial Daily Dose (IR/Onset SL) Maximum Daily Dose (IR/Onset SL/CR)
Adult Women 5 mg 10 mg (IR/SL), 12.5 mg (CR)
Adult Men 5 mg or 10 mg 10 mg (IR/SL), 12.5 mg (CR)
Older Adults (Geriatric) 5 mg (IR) or 6.25 mg (CR) Lowest effective dose

For both older adults and individuals with hepatic impairment, the recommended initial dose for all formulations is the lowest dose available due to reduced clearance and increased sensitivity. The medicine is not recommended for individuals under 18 years of age.

Recent Clinical Evidence

Zolpeduar: Recent Clinical Evidence

This section summarizes research evidence that explored the drug's mechanism and related areas of research. This is a neutral overview of published research; it is not medical advice or a recommendation for use.


Mechanistic Studies and Pharmacodynamics

Studies examined the active compound and evaluated whether it researched a specific biochemical pathway. Research has explored whether combining the compound with a second agent was studied in cases classified as severe, although findings are often limited to short-term assessment.


Clinical Research and Findings

A variety of study designs, including small randomized controlled trials and observational studies, have explored the formulation's focus on target conditions.

  • Sleep Outcomes: Studies investigated endpoints related to sleep duration and initiation by analyzing changes in related biomarkers. In one observational study, participants reported observations at the three-day follow-up. Comparative research included a comparison to previously studied treatments.
  • Combination Research: Studies have examined whether combination regimens examined metrics associated with long-term follow-up. One randomized controlled trial evaluated the formulation in participants with a treatment-resistant condition.

Pharmacokinetics and Study Design

Research in healthy volunteers evaluated the formulation's absorption characteristics. Studies have evaluated this formulation in pediatric participants over 12 to assess its characteristics in that population. Some studies excluded participants with specific pre-existing heart conditions due to protocol design limitations.

Frequently Asked Questions (FAQ)

Common questions about Zolpeduar (FAQ)

Q: How quickly should a person expect Zolpeduar to start working after taking it?

Official product information indicates that immediate-release tablets typically begin to work within approximately 30 minutes. Taking the medicine with or immediately after food may delay the onset of action, which is noted in administration instructions.

Q: What is the typical duration of effect for Zolpeduar?

The immediate-release form generally has a short duration of effect, with a half-life of 2 to 3 hours. The duration of effect can vary, but the medicine is characterized by a relatively short half-life. Extended-release formulations are available, which are intended to help extend the sleep period.

Q: Can Zolpeduar cause rebound insomnia when discontinued?

Regulatory warnings indicate that abrupt discontinuation, especially after prolonged use, may lead to withdrawal symptoms. One of these potential symptoms is rebound insomnia, which is the temporary return or worsening of difficulty sleeping.

Q: What are the common gastrointestinal side effects reported with Zolpeduar?

Based on reports from clinical trials, commonly reported gastrointestinal side effects observed include diarrhea, nausea, dyspepsia, and abdominal pain.

Q: Does taking Zolpeduar affect my sleep architecture or REM sleep?

The medicine belongs to a class of non-benzodiazepine hypnotics. Clinical information suggests that these types of agents have not been shown to have a negative impact on the structure of a person's sleep, which includes important stages like REM (Rapid Eye Movement) sleep.

Q: Are there any over-the-counter (OTC) medicines that should be avoided with Zolpeduar?

Yes, official drug interaction data warns that the risk of additive Central Nervous System (CNS) depression is increased when Zolpeduar is combined with other depressants. This category includes some common over-the-counter medicines, such as certain cold and allergy medications containing antihistamines.

Q: Is it true that the effects of Zolpeduar are stronger for new users?

Official information indicates that the body may develop tolerance to the effects of the drug over time. This tolerance means that the effects may become less pronounced in long-term users compared to when the medicine was initially started.

Q: What do official sources say about the long-term safety of Zolpeduar?

Regulatory guidance authorizes this medicine for short-term use only, typically defined as up to four weeks. Long-term use is discouraged and is associated with risks including dependence, tolerance, and withdrawal upon discontinuation.

Q: Is it important to take Zolpeduar on an empty stomach?

Official instructions state that taking the dose with or immediately after a meal may slow the onset of action. This is why some official instructions recommend taking it on an empty stomach.

Q: What should be done if a dose is missed (informational, non-directive)?

The medicine is strictly limited to a single dose per night and must not be readministered during the same night. If a dose is missed, regulatory guidance states the dose must not be attempted later.

Q: Can people with a history of depression use Zolpeduar?

The FDA label warns that use of this medicine may cause a worsening of depression or lead to the emergence of suicidal thinking. Official guidance indicates that use in patients with a history of depression requires caution due to these potential behavioral risks.

Q: Is Zolpeduar considered a benzodiazepine?

No, Zolpeduar is formally classified as a non-benzodiazepine hypnotic. It is sometimes referred to as a 'Z-drug' because, while it acts on the same general receptor complex in the brain as benzodiazepines, it has a distinct chemical structure.

Q: How does Zolpeduar differ from an older medicine like Valium (diazepam)?

Zolpeduar is more selective in the way it acts on the brain’s GABA receptors compared to older medicines like diazepam. This selectivity means that Zolpeduar produces predominantly sleep-inducing effects with less pronounced muscle relaxant or anti-anxiety properties.

Q: What is the difference between Zolpeduar and other 'Z-drugs' like zaleplon?

Zolpeduar and other 'Z-drugs' (like zaleplon) all belong to the non-benzodiazepine hypnotic class, which facilitates sleep. However, they have different chemical structures and pharmacological properties that can result in varying onset times and durations of action.

Q: Does Zolpeduar cause next-day grogginess or feeling 'hungover'?

Official warnings describe a risk of residual next-day impairment, which can include daytime sleepiness, drowsiness, or impaired psychomotor and cognitive function. The risk is increased if a full night's sleep (7–8 hours) is not obtained.

Q: What are the signs that a person might be experiencing an allergic reaction to Zolpeduar?

Signs of a severe, potentially life-threatening allergic reaction (anaphylaxis or angioedema) may include swelling of the face, lips, tongue, or throat, or trouble breathing. Immediate medical attention is required for these symptoms.

Q: Does the body develop a tolerance to Zolpeduar over time?

Yes, the FDA notes that the drug is associated with tolerance, meaning the effects may lessen over time. This risk is a primary reason for the regulatory guidance limiting its use to short-term periods.

Q: Can Zolpeduar be used to treat middle-of-the-night awakenings?

Yes, specific sublingual tablet formulations are officially indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. This use requires that the user has at least four hours of sleep time remaining.

Q: Can Zolpeduar be used alongside behavioral therapies like CBT-I?

Clinical guidelines often recommend non-pharmacological therapies, such as Cognitive Behavioral Therapy for Insomnia (CBT-I), as a primary approach. The medication may be used alongside these therapies for short-term management, according to established prescribing guidelines.

Q: Does Zolpeduar come in different release forms (e.g., immediate release vs. extended release)?

Yes, the medication is available in several regulatory-approved forms, including immediate-release oral tablets, extended-release oral tablets, and sublingual tablets, which have been developed to address different needs, such as facilitating sleep onset or extending the sleep period.

Q: What should be done if a person experiences nightmares or strange dreams while on Zolpeduar?

Clinical trial data includes reports of abnormal dreams as a potential side effect. The official product information states that any abnormal thinking or behavioral changes should prompt discontinuation of the medicine and a medical evaluation.

Q: Can Zolpeduar cause changes in appetite or lead to weight changes?

Adverse event reports from clinical trials include changes in appetite, such as increased appetite, as well as infrequent reports of weight decrease. These are considered potential side effects documented in official sources.

Q: Can Zolpeduar cause a worsening of restless legs syndrome?

Rare adverse event reports documented in official regulatory sources include an increased severity or occurrence of restless legs syndrome (RLS) as a potential side effect of the medicine.

Q: Why does Zolpeduar sometimes cause a temporary feeling of euphoria or excitement?

Euphoria or feelings of excitement are listed in the official adverse reaction database as infrequent effects occurring in the central nervous system. Official product information states that all abnormal thinking and behavioral changes should be reported to a healthcare professional.

Q: Do studies suggest that Zolpeduar is more or less 'natural' than melatonin?

Zolpeduar is classified as a synthetic chemical compound. Melatonin, by contrast, is a naturally occurring hormone produced by the body. The regulatory classification confirms the non-natural, synthetic origin of Zolpeduar.

Q: What information is available regarding Zolpeduar use in adolescents?

The medicine is not recommended for individuals under 18 years of age due to unestablished safety and effectiveness. Studies examining its use in adolescents for a specific associated condition failed to show effectiveness in reducing the time it takes to fall asleep.

Q: Do certain herbal supplements interact with Zolpeduar?

Yes, aside from St. John's wort, which can reduce effectiveness, other herbal supplements that cause Central Nervous System (CNS) depression, such as valerian root, should be avoided due to the risk of additive sedative effects.

How should Zolpeduar be stored and disposed of?

How to Store and Dispose of Zolpidem Tartrate

Storage of zolpidem tartrate tablets must strictly adhere to regulatory requirements to maintain product stability and prevent misuse. Store the tablets at controlled room temperature, specifically between 20^circ to 25 C (68^circ to 77 F). The medicine must be kept in its original container, which should be tightly closed, and protected from freezing, excessive heat, light, and moisture.

As a controlled substance, zolpidem must be stored in a safe place and kept out of the reach of children. For disposal, the preferred methods are using drug take-back programs or mail-back envelopes. If these are unavailable, unused medicine may be mixed with an undesirable substance, placed in a sealed container, and thrown into household trash; the tablets must not be crushed during this process.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zolpeduar found in:

A-Z Index: